AgelessRx Named One of America’s Fastest-Growing Private Companies by Inc. Magazine

The mission-driven leader in longevity and telehealth earns national recognition on the 2025 Inc. 5000 list for its rapid revenue and membership growth.

Ann Arbor, MI, August 12, 2025 – AgelessRx, a pioneer in longevity and telehealth solutions, has been named to Inc. Magazine’s annual ranking of the fastest-growing private companies in America. The ranking is based on revenue growth over 3 years. It recognizes companies reshaping their industries through steady growth and future-thinking business models.

Key Takeaways

• AgelessRx earned a spot on the Inc. 5000 list, ranked by three-year revenue growth
• The Inc. 5000 has run for 44 years and is considered America’s entrepreneurial benchmark
• AgelessRx targets all 12 hallmarks of aging, where traditional care treats single diagnoses
• The PEARL trial, one of the first large-scale telemedicine Rapamycin studies, was funded by AgelessRx
• The global longevity market is projected to reach $63 billion by 2035, with a 10.37% CAGR

First published 44 years ago, the Inc. The Inc. 5000 list has long measured private business success and serves as a benchmark for entrepreneurship in America. Each year, Inc. features companies from a variety of industries that show strong growth and staying power. AgelessRx joins a group of past recipients that includes well-known names like Microsoft, Zappos, Intuit, Patagonia, and Under Armour.

“We’re honored by Inc.’s recognition, not merely for our rapid growth, but for what it represents,” said Anar Isman, CEO and co-founder of AgelessRx. “It reflects the growing momentum behind a core belief: aging is a disease worth treating, and radically extended healthspan should be the new default. That shift is driving our progress, and we’re here to accelerate it.”

A New Model for Longevity Care

Founded in 2020, AgelessRx is shifting healthcare from reactive to preventive. The first-of-its-kind platform, built expressly for longevity-focused care, makes personalized, healthspan boosting protocols accessible by weaving together prescription therapies, advanced diagnostics, targeted supplements, and expert clinical guidance into a single digital hub.

Feature	Traditional Healthcare	AgelessRx
Care model	Reactive	Preventive
Focus	Single diagnosis or symptom	12 hallmarks of aging
Protocol guidance	General clinical guidelines	Stanford PhD-led Applied Sciences team
Research involvement	Relies on external studies	Runs original clinical trials (e.g., PEARL)
Personalization	Standardized treatment plans	Tailored protocols
Access model	In-person clinic visits	Telehealth

Building Longevity Care Around the Individual

Backed by a Stanford PhD-led Applied Sciences team who both runs clinical trials and vets protocol effectiveness, each protocol is tailored to the individual, guided by US-based clinicians, and continuously updated over time using patient data, such as our Rapamycin DEXA study, to promote healthspan.

Earlier in the year, Inc. also named AgelessRx to its 2025 Best Workplaces list. This is a reflection of its mission-first culture and values-driven growth.

Targeting all 12 hallmarks of aging means looking past a single symptom or diagnosis and paying attention to the underlying biological processes, such as cellular senescence, mitochondrial function, and inflammaging, that shape how a body ages over time. Instead of waiting for a specific condition to appear, this approach looks at the broader picture of how someone is aging and what might help slow that process down.

That broader view is what makes personalized protocols different from standardized clinical care. Instead of following a one-size-fits-all treatment plan, clinicians build each person’s protocol around their labs, health history, and goals. They then adjust it over time as new data comes in. Delivering this kind of care through telehealth also matters for access. It lets people work with US-licensed clinicians and get thorough, ongoing support without needing to live near a specialty clinic.

“For us, growth has always been about impact,” said Courtney Frederick, Vice President of People and Finance. “This honor reflects the work of a dedicated team that’s stayed grounded in why we started, our mission, and who we’re here to help. That’s what makes this moment meaningful.”

The Story Behind AgelessRx

From Investment Funds to Longevity Care

CEO Anar Isman founded AgelessRx after spending fifteen years in investment funds before turning his focus to longevity. After struggling to get a clinician to prescribe his mother a medication with potential longevity benefits, he saw firsthand how difficult it was for healthy people to access treatments aimed at extending healthspan instead of treating a single diagnosis. That experience led him to partner with a physician co-founder known as Dr. Z, and later with Jonn Behrman. Their goal was to build a platform that could make science-backed longevity support more accessible.

Funding the PEARL Rapamycin Trial

In its early years, AgelessRx also helped organize and fund PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity), one of the first large-scale, nationwide telemedicine trials studying rapamycin for longevity, run in affiliation with the University of California with Dr. James Watson at UCLA as principal investigator. The double-blind, placebo-controlled study was designed to test whether rapamycin may support healthy aging in adults, combining extensive PEARL trial findings from lab testing with donor and crowdfunding support to help get the research off the ground.

What made PEARL stand out was its design. Being double-blind and placebo-controlled meant neither participants nor researchers knew who received Rapamycin versus a placebo, a gold-standard approach that helps keep results reliable. Pairing that rigor with real-world crowdfunding and donor support, alongside careful lab testing, let a small team pursue a question that larger institutions had not yet taken on at this scale.

Along the way, the trial turned up findings the team had not set out to study. Some participants showed changes in bone mineral density, a result that prompted our team to look closer at skeletal health.

The Road Ahead for AgelessRx

The global longevity market is expected to reach $63 billion by 2035, with a CAGR of 10.37%, as consumer demand continues to grow for prevention-first care models. AgelessRx is leading the way in science-backed, human-first longevity care with a model that’s data-driven, personalized, thorough, and accessible, shaping the future of what modern aging can be.

Outside recognition backs this up. AgelessRx was named one of 10 finalists in the XPRIZE Healthspan Finals, selected from a field of more than 600 teams across 58 countries. Reaching the finals gave AgelessRx’s Research Team a third party check on its scientific approach, offering a marker of credibility beyond internal review.

A simple idea shapes much of that approach: a single agent rarely tells the whole story of aging. AgelessRx’s Research Team studies how gerotherapeutics, treatments aimed at the biology of aging itself, work together instead of alone, with the belief that thoughtfully paired compounds can support healthspan more fully than any one treatment on its own. That thesis continues to shape how clinicians build and adjust patient protocols over time.

As this research matures, the goal stays simple: give people real, personalized options for aging well, backed by data instead of guesswork. For the next generation of patients, that could mean starting healthspan focused care earlier, with clinicians and evidence guiding each step along the way.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.